Immunization with recombinant human granulocyte-macrophage colony- stimulating factor as a vaccine adjuvant elicits both a cellular and humoral response to recombinant human granulocyte-macrophage colony-stimulating factor

Blood

Volumn 93, Issue 8, 1999, Pages 2653-2659

  McNeel, Douglas G ^a,b   Schiffman, Kathy ^a   Disis, Mary L ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ACTIVE IMMUNIZATION; ANTIBODY RESPONSE; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; ARTICLE; HUMAN; IMMUNOGENICITY; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

EID: 0033561444     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v93.8.2653.408k07_2653_2659     Document Type: Article

References (41)

1. Vial T, Descotes J: Clinical toxicity of cytokines used as haemopoietic growth factors. Drug Saf 13:371, 1995
2. Steward WP, Scarffe JH, Austin R, Bonnem E, Thatcher N, Morgenstern G, Crowther D: Recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF) given as daily short infusions - a phase I dose-toxicity study. Br J Cancer 59:142, 1989
3. Locker GJ, Simonitsch I, Mader RM, Warlamides E, Gnant MFX, Jakesz R, Rainer H, Steger GG: Cutaneous side effects in breast cancer patients treated with cytostatic polychemotherapy and rh GM-CSF: Immune phenomena or drug toxicity? Breast Cancer Res Treat 34:213, 1995
4. Ragnhammar P, Friesen H-J, Frödin J-E, Lefvert A-K, Hassan M, Österborg A, Mellstedt H: Induction of anti-recombinant human granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived) antibodies and clinical effects in nonimmunocompromised patients. Blood 84:4078, 1994
5. Wadhwa M, Bird C, Fagerberg J, Gaines-Das R, Ragnhammar P, Mellstedt H, Thorpe R: Production of neutralizing granulocyte-macrophage colony-stimulating factor (GM-CSF) antibodies in carcinoma patients following GM-CSF combination therapy. Clin Exp Immunol 104:351, 1996
6. Thompson JA, Lee DJ, Kidd P, Rubin E, Kaufmann J, Bonnem EM, Fefer A: Subcutaneous granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome: toxicity, pharmacokinetics, and hematological effects. J Clin Oncol 7:629, 1989
7. Gribben JG, Devereux S, Thomas NSB, Keim M, Jones HM, Goldstone AH, Linch DC: Development of antibodies to unprotected glycosylation sites on recombinant human GM-CSF. Lancet 335:434, 1990
8. Vadas MA, Nicola NA, Metcalf D: Human granulocyte-macrophage colony stimulating factor is a neutrophil activator. Nature 314:361, 1985
9. Weller PF: Cytokine regulation of eosinophil function. Clin Immunol Immunopathol 62:855, 1992
10. Markowicz S, Engleman EG: Granulocyte-macrophage colony-stimulating factor promotes differentiation and survival of human peripheral blood dendritic cells in vitro. J Clin Invest 85:955, 1990
11. Larsen CP, Ritchie SC, Hendrix R, Linsley PS, Hathcock KS, Hodes RJ, Lowry RP, Pearson TC: Regulation of immunostimulatory function and costimulatory molecule (B7-1 and B7-2) expression on murine dendritic cells. J Immunol 152:5208, 1994
12. Disis ML, Bernhard H, Shiota FM, Hand SL, Gralow JR, Huseby ES, Gillis S, Cheever MA: GM-CSF: An effective adjuvant for protein and peptide based vaccines. Blood 88:202, 1996
13. Sanda MG, Ayyagari SR, Jaffee EM, Epstein JI, Clift SL, Cohen LK, Dranoff G, Pardoll DM, Mulligan RC, Simons JW: Demonstration of a rational strategy for human prostate cancer gene therapy. J Urol 151:622, 1994
14. Thompson RC, Pardoll DM, Jaffee EM, Ewend MG, Thomas MC, Tyler BM, Brem H: Systemic and local paracrine cylokine therapies using transduced tumor cells are synergistic in treating intracranial tumors. J Immunother Emphasis Tumor Immunol 19:405, 1996
15. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC: Vaccination with irradiated tumor cells engineered to secrete muring granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 90:3539, 1993
16. Kurane S, Arca MT, Aruga A, Krinock RA, Krauss JC, Chang AE: Cytokines as an adjuvant to tumor vaccines: Efficacy of local methods of delivery. Ann Surg Oncol 4:579, 1997
17. Simons JW, Jaffee EM, Weber CE, Levitsky HI, Nelson WG, Carducci MA, Lazenby AJ, Cohen LK, Finn CC, Clift SM, Hauda KM, Beck LA, Leiferman KM, Owens AH Jr, Piantadosi S, Dranoff G, Mulligan RC, Pardoll DM, Marshall FF: Bioactivitiy of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res 57:1537, 1997
18. Berns AJ, Clift S, Cohen LK, Donehower RC, Dranoff G, Hauda KM, Jaffee EM, Lazenby AJ, Levitsky HI, Marshall FF, Mulligan RC, Nelson WG, Owens AH, Pardoll DM, Parry G, Partin AH, Piantadosi S, Simons JW, Zabora JR: Phase I study of non-replicating autologous tumor cell injections using cells prepared with or without GM-CSF gene transduction in patients with metastatic renal cell carcinoma. Hum Gene Ther 6:347, 1995
19. Ellem KA, O'Rourke MG, Johnson GR, Parry G, Misko IS, Schmidt CW, Parsons PG, Burrows SR, Cross S, Fell A, Li CL, Bell JR, Dubois G, Moss DJ, Good MF, Kelso A, Cohen LK, Dranoff G, Mulligan RC: A case report: Immune responses and clinical course of the first human use of granulocyte/macrophage-colony-stimulating-factor-transduced autologous melanoma cells for immunotherapy. Cancer Immunol Immunother 44:10, 1997
20. Tao MH, Levy R: Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma. Nature 362:755, 1993
21. Hakim I, Levy S, Levy R: Anine-amino acid peptide from IL-1β augments antitumor immune responses induced by protein and DNA vaccines. J Immunol 157:5503, 1996
22. Wortham C, Grinberg L, Kaslow DC, Briles DE, McDaniel LS, Lees A, Flora M, Snapper CM, Mond JJ: Enhanced protective antibody responses to PspA after intranasal or subcutaneous injections of PspA genetically fused to granulocyte-macrophage colony-stimulating factor or interleukin-2. Infect Immun 66:1513, 1998
23. Chen TT, Levy R: Induction of autoantibody responses to GM-CSF by hyperimmunization with an Id-GM-CSF fusion protein. J Immunol 154:3105, 1995
24. Towbin H, Staehelin T, Gordon J: Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications. Proc Natl Acad Sci USA 76:4350, 1979
25. Wadhwa M, Bird C, Fagerberg J, Gaines-Das R, Ragnhammar P, Mellstedt H, Thorpe R: Production of neutralizing granulocyte-macrophage colony-stimulating factor (GM-CSF) antibodies in carcinoma patients following GM-CSF combination therapy. Clin Exp Immunol 104:351, 1996
26. Disis ML, Grabstein KH, Sleath PR, Cheever MA: HER-2/neu peptide vaccines elicit T cell immunity to the HER-2/neu protein in patients with breast and ovarian cancer. Proc Am Soc Clin Oncol 17:97a, 1998
27. Disis ML, Cheever MA: HER-2/neu oncogenic protein: Issues in vaccine development. Crit Rev Immunol 18:37, 1998
28. Fagerberg J: Granulocyte-macrophage colony-stimulating factor as an adjuvant in tumor immunotherapy. Med Oncol 13:155, 1996
29. Pardoll DM: Paracrine cytokine adjuvants in cancer immunotherapy. Annu Rev Immunol 13:399, 1995
30. Nohria A, Rubin RH: Cytokines as potential vaccine adjuvants. Biotherapy 7:261, 1994
31. Svenson M, Hansen MB, Ross C, Diamant M, Rieneck K, Nielsen H, Bendtzen K: A ntibody to granulocyte-macrophage colony-stimulating factor is a dominant anti-cytokine activity in human IgG preparations. Blood 91:2054, 1998
32. Sallusto F, Lanzavecchia A: Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/ macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α. J Exp Med 179:1109, 1994
33. Fischer H-G, Frosch S, Reske K, Reske-Kunz AB: Granulocyte-macrophage colony-stimulating factor activates macrophages derived from bone marrow cultures to synthesis of MHC class II molecules and to augmented antigen presentation function. J Immunol 141:3882, 1988
34. Ahlers JD, Dunlop N, Alling DW, Nara PL, Berzofsky JA: Cytokine-in-adjuvant steering of the immune response phenotype to HIV-1 vaccine constructs. J Immunol 158:3947, 1997
35. Kaplan G, Walsh G, Guido LS, Meyn P, Burkhardt RA, Abalos RM, Barker J, Frindt PA, Fajardo TT, Celona R: Novel responses of human skin to intradermal recombinant granulocyte/macrophage-colony-stimulating factor: Langerhans cell recruitment, keratinocyte growth, and enhanced wound healing. J Exp Med 175:1717, 1992
36. Tarr PE, Lin R, Muellern EA, Kovarik JM, Guillaume M, Jones TC: Evaluation of tolerability and antibody response after recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) and a single dose of recombinant hepatitis B vaccine. Vaccine 14:1199, 1996
37. Hess G, Kreiter F, Kosters W, Deusch K: The effect of granulocyte-macrophage colony-stimulating factor (GM-CSF) on hepatitis B vaccination in haemodialysis patients. J Viral Hepat 3:149, 1996
38. Hadden JW: T cell adjuvants. Int J Immunopharmacol 16:703, 1994
39. Steis RG, Smith JW, Urba WJ, Clark JW, Itri LM, Evans LM, Schoenberger C, Longo DL: Resistance to recombinant interferon alfa-2a in hairy-cell leukaemia associated with neutralizing anti-interferon antibodies. N Engl J Med 318:1409, 1988
40. Antonelli G, Currenti M, Turriziani O, Dianzani F: Neutralizing antibodies to interferon-α: Relative frequency in patients treated with different interferon preparations. J Infect Dis 163:882, 1991
41. Cantrell MA, Anderson D, Carretti DP, Price V, McKereghan K, Tushinski RJ, Mochizuki DY, Larsen A, Grabstein K, Gillis S, Cosman D: Cloning, sequence, and expression of a human granulocyte/ macrophage colony-stimulating factor. Proc Natl Acad Sci USA 82: 6250, 1985